Simple blood test could spot cancer early – 10,000 volunteers needed
NCT ID NCT06192875
First seen Jun 27, 2026 · Last updated Sep 15, 2026 · Updated 2 times
Summary
This study aims to find normal values for a new blood and urine test that might detect cancer early. Researchers at Mayo Clinic will collect samples from 10,000 adults without known cancer and review their medical records. The goal is to set a baseline for future cancer screening tests.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple blood or urine test that helps detect cancer earlier, potentially improving treatment outcomes.
- What could go wrong
- This is an early-stage study focused on establishing normal values, not yet proving the test can reliably detect cancer. It may not lead to a usable screening tool.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 10,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2015
- Expected to finish
-
Dec 2035
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients without a known internal (non-cutaneous) cancer or a history of an internal cancer
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 10,000 patients without a known internal (non-cutaneous) cancer or a history of an internal cancer * To balance age, rough recruitment goals will be set for the following subsets: 18-39 years, 40-49 years , 50-59 years , 60-69 years , 70-79 years , and \>= 80 years * To balance sex, roughly half of the participants recruited within each age subset will be women * Roughly half of all participants will have had a colonoscopy or colon x-ray within the past 5 years, or Cologuard® test in the last 3 years which were negative for cancer and precancerous lesions * Roughly half of all participants will have had a chest x-ray within the past 5 years which was negative for cancer * Roughly half of women participants will have had a mammography in the past 5 years which was negative for cancer * An attempt will be made to recruit minimums (parentheses) of the following subsets: men with normal Prostate-specific antigen (PSA) level (200); diabetes mellitus (200); connective tissue diseases like rheumatoid arthritis, systemic lupus erythematosus, and scleroderma (100); chronic obstructive lung disease (100); inflammatory bowel disease or cirrhosis (100), and pancreatitis (100) * To assess the effects of other common covariates, specific recruitment targets will not be set. Rather, data obtained on all participants will include BMI, smoking (past/present), alcohol consumption, pregnant status (women), and selected medications (steroidal and non-steroidal anti-inflammatory drugs, statins, anti-hypertensives, and anti-depressants) Exclusion Criteria: * Patients has a past or current diagnosis of invasive cancer (this does not include basal cell or squamous cell skin cancers) * Patient has had a solid organ transplant * Inability to give informed consent URINE EXCLUSIONS * Patient has transurethral instrumentation (cystoscopy, placement of urinary catheter) within the 7 days prior to sample collection * Patient has chronic indwelling urinary catheter * Patient has had a urinary tract infection within the 14 days prior to sample collection SALIVA EXCLUSIONS * Patient has known clinically significant xerostomia * Patient has known recent (within 30 days prior to collection) active upper respiratory tract infection or anogenital infection
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hematopoietic and lymphoid system neoplasm are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a vaccine stop GI cancers from returning?
- Can a phone app help childhood cancer survivors keep track of their health?
- Can the way we word cancer research invitations boost participation?
- A chill pill for Chemo's side effects? cooling therapy and a Blood-Flow drug take on nerve pain
- Wearable tech could spot Post-Surgery problems early
- Can an AI chatbot ease the aftermath of cancer?